The aim of this study is to compare the effectiveness of Rezum therapy versus Prostatic Artery Embolization in managing moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), with the primary endpoint being the improvement in the International Prostate Symptom Score (IPSS) over a 6-month follow-up period. Secondary endpoints include changes in post-void residual urine (PVR), maximum urinary flow rate (Qmax), patient-reported quality of life (QoL), and the preservation of ejaculatory and overall sexual function as assessed by validated questionnaires. This study aims to provide evidence-based guidance for optimizing treatment strategies for men with BPH, particularly those seeking alternatives to pharmacological therapy.
Age ≥50 years.
IPSS ≥13.
Prostate volume between 30-80 mL.
Maximum urinary flow rate (Qmax) ≤15 mL/sec in patients with voiding LUTs.
History or suspicion of prostate cancer.
Previous prostate surgery or minimally invasive BPH intervention.
Neurological bladder dysfunction.
Active urinary tract infection.